Norway, Oct. 28 -- Circio Holding ASA, a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces the materials for its oral and two poster presentations that are being delivered at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Hamburg, Germany.In the oral presentation, Circio s CTO Dr. Thomas B Hansen presents the latest developments for its circVec platform and its potential for in vivo CAR-T therapy, an area attracting significant momentum in the life sciences industry. Circio s approach formulates circVec DNA constructs into LNP particles with the aim to establish a novel technology platform for potent, durable and immune-quiet CAR express...